Comparison
Glepaglutide vs. Pasireotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
no data
396091-73-9
Molecular weight
no data
1047.21 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Glepaglutide and Pasireotid?
- Glepaglutide is classified as "Research other", while Pasireotid is classified as "Research other". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Glepaglutide or Pasireotid?
- The highest available evidence level is "Human RCT" for Glepaglutide and "Human RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Glepaglutide and Pasireotid in Germany and the United States?
- Germany: Glepaglutide — Unapproved, Pasireotid — Prescription. United States: Glepaglutide — Unapproved, Pasireotid — Prescription. These are factual summaries with source and review date on the individual pages.